Physicians are likely to see a demand for “Pink Viagra,” as 73 percent of female survey participants said they were likely to discuss low sex drive with a doctor; however, physicians could need to educate patients on their options as 70 percent of female survey participants said they had never heard of Flibanserin before participating in the survey.
In addition to the survey, Treato compiled and analyzed thousands of online conversations happening about “Pink Viagra.” Ironically the top concerns being discussed online by women interested in taking the medication were tiredness, headaches and drowsiness. Popular topics being discussed online in connection to the medication were depression and menopause, which are conditions that can also cause low sex drive.
“Analyzing online patient conversations is a key resource in understanding the unmet needs of a population,” says Ido Hadari, CEO of Treato. “Through our collected insights, it became clear that an overwhelming majority of women want access to a female version of Viagra. This is a huge market opportunity for pharma and healthcare advocates as well a significant opportunity to improve female consumers quality of life.”
Find more information on Treato’s “Pink Viagra” data analysis here.